Premium
HIV‐specific CD8 + T‐cell proliferation is prospectively associated with delayed disease progression
Author(s) -
McKin Lyle R,
Kaul Rupert,
Kimani Joshua,
Nagelkerke Nico J,
Wachihi Charles,
Fowke Keith R,
Ball Terry Blake,
Plummer Francis A
Publication year - 2012
Publication title -
immunology and cell biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.999
H-Index - 104
eISSN - 1440-1711
pISSN - 0818-9641
DOI - 10.1038/icb.2011.44
Subject(s) - elispot , immunology , cd8 , immune system , medicine , t cell , prospective cohort study , cytotoxic t cell , biology , biochemistry , in vitro
Human immunodeficiency virus (HIV)‐specific CD8 + T‐cell proliferation is consistently correlated with enhanced host HIV immune control, but whether proliferative responses are a cause or consequence of immune protection is unclear. We measured Env‐specific CD8 + T‐cell proliferation and interferon (IFN)‐γ secretion in HIV‐infected participants with CD4 counts >200, who then completed 121 person‐years of prospective follow‐up to monitor HIV disease progression. In all, 13 of 31 participants (42%) reached end point during longitudinal follow‐up. Strong Env‐specific CD8 + T‐cell proliferation (>10% of CD8 + T cells) was observed in 14/31 participants at baseline, and this was associated with a longer time to HIV disease progression end point, stratified baseline CD4 count ( P =0.016). No associations were observed for IFN‐γ ELISPOT responses and progression ( P >0.2). Strong proliferation remained significant in multivariate Cox regression analyses ( P =0.044) as an independent predictor of delayed HIV disease progression, along with baseline CD4 count ( P =0.04). Duration of HIV infection was associated with more rapid progression in univariate, but not multivariate, analysis ( P =0.112). Age and baseline viral load were not predictive of progression. HIV‐specific CD8 + T‐cell proliferation was a correlate of protective immunity in this prospective study; such responses may be important for HIV vaccine protection.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom